Q-omics provides the consensus-scored ZNF175 profile across patient tissues and cancer cell-line models. ZNF175 expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, ZNF175 is differentially expressed in 12, with the highest sampling consensus in UCEC. Additionally, ZNF175 RNA expression shows 21,112 significant gene co-expression associations, with the highest sampling consensus in KIRP. Together, these results highlight KIRC, UCEC, and KIRP as cancer lineages where ZNF175 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ZNF175 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ZNF175 survival associations across molecular data types. ZNF175 RNA expression shows survival associations in the most cancer types (25), followed by mutation status (5) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ZNF175 RNA expression–survival associations across cancer types. High ZNF175 expression shows unfavorable associations in MESO, LGG, LUSC, CESC and DLBC, but favorable associations in KIRC. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for ZNF175 RNA expression.
This table summarizes ZNF175 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12, while mass-spec protein shows differences in 3. The strongest signals are observed in UCEC for RNA and COAD for protein.
This table ranks reproducible tumor–normal expression differences for ZNF175. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ZNF175 shows lower tumor expression in UCEC, LUAD, THCA and COAD and higher tumor expression in BLCA and HNSC. The UCEC box plot shows higher ZNF175 RNA expression in normal versus tumor tissue (log2 FC = −1.009, t-test p < 0.001).
This table shows molecular features associated with ZNF175 in patient tissues and cancer cell lines. In patient samples, ZNF175 shows the broadest associations at the RNA and protein expression levels, with KIRP recurring as the lineage with the largest associated feature set. In cancer cell lines, ZNF175 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in PANCREAS, while CRISPR and shRNA rows add functional-dependency signals in LUNG_NSCLC_LUSC and BLOOD_Leukemia.
